TCGA-READ samples stratified into C1 and C2 subtypes by survival and immune profiles revealed that C2 tumors derive markedly greater benefit from CTLA-4/PD-1 blockade than C1 tumors, underscoring the value of molecular subtyping in guiding precision immunotherapy.<h4>Conclusions</h4><i>FAM135A</i> was identified as a potential tumor vaccine antigen, and an immune subtype analysis was conducted in different patients. The gene discussed is CTLA4; the disease is neoplasm.